Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural Epublish 11 citations
PubMed: 34685741 DOI: 10.3390/cells10102764
Comparative Mutational Profiling of Hematopoietic Progenitor Cells and Circulating Endothelial Cells (CECs) in Patients with Primary Myelofibrosis.
Cells 10(10)
Authors: Mirko Farina, Simona Bernardi, Nicola Polverelli, Mariella D'Adda, Michele Malagola, Katia Bosio, Federica Re, Camillo Almici, Andrew Dunbar, Ross L Levine, Domenico Russo
Affiliations
- Unit of Blood Diseases and Bone Marrow Transplantation, Cell Therapies and Hematology Research Program, Department of Clinical and Experimental Sciences, University of Brescia, ASST Spedali Civili di Brescia, P.le Spedali Civili, 1, 25123 Brescia, Italy.
- CREA Laboratory (Centro di Ricerca Emato-Oncologica AIL), ASST Spedali Civili di Brescia, 25123 Brescia, Italy.
- Hematology Unit, ASST Spedali Civili di Brescia, 25123 Brescia, Italy.
- Laboratory for Stem Cells Manipulation and Cryopreservation, Department of Transfusion Medicine, ASST Spedali Civili di Brescia, 25123 Brescia, Italy.
- Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Abstract
A role of endothelial cells (ECs) in Primary Myelofibrosis (PMF) was supposed since mutation was found in endothelial precursor cells (EPCs) and in ECs captured by laser microdissection. By Cell Search method, the circulating endothelial cells (CECs) from 14 PMF patients and 5 healthy controls have been isolated and compared by NGS with CD34+Hematopoietic stem and progenitors cells (HSPCs) for panel of 54 myeloid-associated mutations. PMF patients had higher levels of CECs. No mutation was found in HSPCs and CECs from controls, while CECs from PMF patients presented several somatic mutations. 72% of evaluable patients shared at least one mutation between HSPCs and CECs. 2 patients shared the mutation, together with , , and , , respectively. 6 out of 8 shared only NON MPN-driver mutations: and in one case; individual paired mutations in , , , and , in the other cases. In conclusion, 70% of PMF patients shared at least one mutation between HSPCs and CECs. These latter harbored several myeloid-associated mutations, besides mutation. Our results support a primary involvement of EC in PMF and provide a new methodological approach for further studies exploring the role of the "neoplastic" vascular niche.
MeSH
Mutation, Primary Myelofibrosis, Hematopoietic Stem Cells, Endothelial Cells
Cited by
- Endothelial heterogeneity in bone marrow: insights across development, adult life and leukemia. Leukemia, 2025
- Chorea and Cognitive Impairment in JAK2V617F-Positive Myeloproliferative Disorders: A Case Report and Literature Review. Medicina (Kaunas), 2024
- Myeloproliferative Neoplasms: Contemporary Review and Molecular Landscape. Int J Mol Sci, 2023
- Exploring the Molecular Aspects of Myeloproliferative Neoplasms Associated with Unusual Site Vein Thrombosis: Review of the Literature and Latest Insights. Int J Mol Sci, 2024